Compare
Geron Corp vs Standard Biotools Inc. vs Nuvation Bio Inc. vs Septerna, Inc.
| Latest fiscal year | Geron Corp GERN | Standard Biotools Inc. LAB | Nuvation Bio Inc. NUVB | Septerna, Inc. SEPN |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $85.33M | $62.90M | $45.95M |
| Revenue growth (YoY) | n/a | -6.2% | +699.0% | n/m |
| Gross margin | n/a | 49.9% | n/a | n/a |
| Operating margin | n/a | -129.2% | -338.7% | -148.6% |
| Net margin | n/a | -87.8% | -325.3% | -106.4% |
| Net income | -$83.50M | -$74.90M | -$204.63M | -$48.88M |
| EPS (Diluted) | -$0.13 | -$0.20 | -$0.60 | -$1.10 |
| Operating cash flow | -$111.04M | -$74.34M | -$173.43M | $110.19M |
| Free cash flow | n/a | -$82.65M | n/a | $109.67M |
| Cash & equivalents | $77.56M | $120.86M | $164.09M | $120.72M |
| Total assets | $570.54M | $567.75M | $594.82M | $596.19M |
| Total liabilities | $344.67M | $143.46M | $289.11M | $214.26M |
| Shareholders' equity | $225.87M | $424.29M | $305.72M | $381.93M |
| Return on year-end equity | -37.0% | -17.7% | -66.9% | -12.8% |
| Shares outstanding | 639.86M | 386.38M | 337.84M | 44.81M |
Revenue, most recent five fiscal years
| Fiscal year | Geron Corp | Standard Biotools Inc. | Nuvation Bio Inc. | Septerna, Inc. |
|---|---|---|---|---|
| Latest | $237.0K Ended 2023-12-31 | $85.33M Ended 2025-12-31 | $62.90M Ended 2025-12-31 | $45.95M Ended 2025-12-31 |
| 1 year earlier | $596.0K Ended 2022-12-31 | $91.01M Ended 2024-12-31 | $7.87M Ended 2024-12-31 | $1.07M Ended 2024-12-31 |
| 2 years earlier | $1.39M Ended 2021-12-31 | $106.34M Ended 2023-12-31 | $0 Ended 2023-12-31 | $151.0K Ended 2023-12-31 |
| 3 years earlier | $253.0K Ended 2020-12-31 | $97.95M Ended 2022-12-31 | n/a | n/a |
| 4 years earlier | $460.0K Ended 2019-12-31 | $130.58M Ended 2021-12-31 | n/a | n/a |